Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Breast Cancer
Interventions: DRUG: Neratinib|DRUG: Capmatinib
Sponsor: M.D. Anderson Cancer Center
Collaborators: Celcuity Inc|Novartis|Puma Biotechnology, Inc.